Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer

被引:136
作者
John P Duffy
Guido Eibl
Howard A Reber
Oscar J Hines
机构
[1] Section of Gatrointestinal Surgery, The David Geffen School of Medicine, UCLA, Los Angeles
关键词
Vascular Endothelial Growth Factor; Pancreatic Cancer; Pancreatic Cancer Cell; Vascular Endothelial Growth Factor Expression; Human Pancreatic Cancer;
D O I
10.1186/1476-4598-2-12
中图分类号
学科分类号
摘要
As with other solid tumors, the growth and metastasis of pancreatic cancer is critically dependent on tumor angiogenesis. A major stimulus for a tumor's recruitment of additional blood vessels is cellular hypoxia, a condition which is especially pronounced in this neoplasm. Hypoxia induces transcriptional activation of genes that alter cellular metabolism and promote neoangiogenesis. Pancreatic cancer cells have demonstrated activation of such adaptive pathways even in the absence of hypoxia. A highly-angiogenic response in this neoplasm correlates with increased tumor growth, increased metastasis, and decreased survival. Pancreatic cancers expressing high levels of vascular endothelial growth factor, a potent pro-angiogenic cytokine, also have a higher incidence of metastasis and poorer prognosis. Pancreatic cancer cells uniquely express receptors for vascular endothelial growth factor, indicating a role for an autocrine loop in tumor proliferation and invasion. Multiple experimental anti-angiogenic strategies, many of which target vascular endothelial growth factor, reduce pancreatic cancer growth, spread, and angiogenesis. Anti-angiogenic treatments for pancreatic cancer will likely be most effective when used as an integral part of a combination chemotherapeutic regimen. © 2003 Duffy et al; licensee BioMed Central Ltd.
引用
收藏
页数:10
相关论文
共 94 条
  • [1] Jemal A., Thomas A., Murray T., Thun M., Cancer statistics, 2002, CA Cancer J. Clin., 52, pp. 23-47, (2002)
  • [2] Folkman J., Tumor angiogenesis: Therapeutic implications, N. Engl. J. Med., 285, pp. 1182-1186, (1971)
  • [3] Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J., Siegel N.R., Leimgruber R.M., Feder J., Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis, J. Clin. Invest., 84, pp. 1470-1478, (1989)
  • [4] O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J., Endostatin: An endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, pp. 277-285, (1997)
  • [5] Moscatelli D., Presta M., Joseph-Silverstein J., Rifkin D.B., Both normal and tumor cells produce basic fibroblast growth factor, J. Cell Physiol., 129, pp. 273-276, (1986)
  • [6] Fett J.W., Strydom D.J., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., Vallee B.L., Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells, Biochemistry, 24, pp. 5480-5486, (1985)
  • [7] Folkman J., Klagsbrun M., Angiogenic factors, Science, 235, pp. 442-447, (1987)
  • [8] Kerbel R.S., Tumor angiogenesis: Past, present, and the near future, Carcinogenesis, 21, pp. 505-515, (2000)
  • [9] Richard D.E., Berra E., Pouyssegur J., Angiogenesis: How a tumor adapts to hypoxia, Biochem. Biophys. Res. Commun., 266, pp. 718-722, (1999)
  • [10] Giatromanolaki A., Harris A.L., Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer, Anticancer Res., 21, pp. 4317-4324, (2001)